Stay updated on HBI-8000 Combo with Nivolumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the HBI-8000 Combo with Nivolumab in Solid Tumors Clinical Trial page.

Latest updates to the HBI-8000 Combo with Nivolumab in Solid Tumors Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page now presents the completed NCT02718066 study record for HBI-8000 in combination with nivolumab, including its design, participant criteria, study locations, outcomes, and record dates. It also includes study protocol and statistical analysis plan documents.SummaryDifference63%

- Check18 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0, while the page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check25 days agoChange DetectedA site-wide NIH banner announces a transition-related update and says that “Super Intelligence” may appear in place of “Artificial Intelligence” across NIH content.SummaryDifference1%

- Check32 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check60 days agoChange DetectedThe study record page now shows a 403 Forbidden error instead of the study details, indicating restricted access to the record. This blocks viewing the study information on the NCT02718066 page.SummaryDifference21%

Stay in the know with updates to HBI-8000 Combo with Nivolumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the HBI-8000 Combo with Nivolumab in Solid Tumors Clinical Trial page.